drugset / Trial / NCT05641324
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.
Timeline
- Start
- 2023-02-10
- Primary completion
- 2023-07-12
- Completion
- 2023-07-12
Outcome
Outcome not reported
Stopped (Enrollment): “The study was ended due to a lack of recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANV419 | Protein / enzyme biologic | — | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |